Tauchert S, di Liberto A, Cordes T, Thill M, Salehin D, Friedrich M
Department of Gynaecology and Obstetrics, Caritas Hospital St Theresia, Saarbrücken, Germany.
Clin Exp Obstet Gynecol. 2009;36(4):219-25.
A novel immunoassay specific for the osteoclast-produced tartrate-resistant acid phosphatase TRAP isoform 5b was developed some years ago. By means of this assay, the usefulness of serum TRAP in monitoring the response to palliative treatment with clodronate in breast cancer patients with bone metastases was studied. Serum TRAP was examined for correlation with the activity of bone osteoclasts in these patients.
Seventeen patients took part in this study taking 1600 mg clodronate daily as a tablet for five months. Eleven of these patients were evaluated.
TRAP activity correlated well with the grade of bone metastases and with the number of locations in the body. During the therapy with clodronate, TRAP activity in serum decreased.
We conclude that the measurement of TRAP is useful in monitoring treatment with bisphosphonate clodronate in patients with bone metastatic breast cancer.
数年前开发了一种针对破骨细胞产生的抗酒石酸酸性磷酸酶TRAP同工型5b的新型免疫测定法。通过该测定法，研究了血清TRAP在监测骨转移乳腺癌患者使用氯膦酸盐进行姑息治疗的反应中的作用。检测了这些患者血清TRAP与骨破骨细胞活性的相关性。
17名患者参与本研究，每天服用1600mg氯膦酸盐片剂，持续5个月。对其中11名患者进行了评估。
TRAP活性与骨转移分级及身体受累部位数量密切相关。在氯膦酸盐治疗期间，血清中TRAP活性降低。
我们得出结论，TRAP的测量对于监测骨转移性乳腺癌患者使用双膦酸盐氯膦酸盐的治疗是有用的。
